Inflammatory Bowel Disease and Gallstones: Risks & Management

Epidemiology – how common are gallstones in IBD?

Patients with inflammatory bowel disease (IBD) – both Crohn’s disease (CD) and ulcerative colitis (UC) – have a significantly higher prevalence of gallstones compared to the general population.

• General population: 10‑15% (cholesterol stones).
• Crohn’s disease: 15‑30% (up to 40% with ileal involvement).
• Ulcerative colitis: 10‑20% (still elevated but lower than Crohn’s).
• Ileal resection (Crohn’s): 30‑50% within 10 years.

Gallstones in IBD are predominantly cholesterol stones (unlike hemolytic conditions which cause pigment stones), but pigment stones can occur with chronic hemolysis from malnutrition or vitamin K deficiency (rare).

Mechanisms: bile acid malabsorption, ileal disease, and more

Multiple pathophysiologic factors contribute to lithogenesis in IBD:

• Bile acid malabsorption (BAM): The terminal ileum reabsorbs bile acids. In Crohn’s ileitis or after ileal resection, bile acids are lost in the stool. The liver compensates by increasing bile acid synthesis, but the bile acid pool becomes depleted relative to cholesterol. This results in lithogenic bile (cholesterol supersaturation).
• Gallbladder hypomotility: Chronic inflammation, malnutrition, and prolonged fasting (during flares or hospitalisations) reduce gallbladder emptying, promoting sludge and stone formation.
• Altered enterohepatic circulation: Disrupted feedback loops lead to abnormal bile composition.
• Chronic inflammation: Systemic inflammatory cytokines may affect cholesterol metabolism and gallbladder function.
• Nutritional deficiencies: Malabsorption of fat‑soluble vitamins, low‑fat diets (prescribed in some IBD patients) can increase bile cholesterol saturation.
• Total parenteral nutrition (TPN): IBD patients with intestinal failure on TPN have extremely high gallstone risk (up to 50% within 1 year) due to biliary stasis.

Risk factors – ileal resection, Crohn’s location, disease duration

Specific predictors for gallstones in IBD:

• Ileal Crohn’s disease (especially with strictures or fistulae): Highest risk.
• Ileal resection: Risk increases with length of resection. Even limited (<30 cm) resection increases risk modestly; >50 cm markedly increases risk.
• Long disease duration: >10‑15 years of IBD.
• History of small bowel resection (any cause).
• TPN dependence.
• Frequent hospitalisations (leading to fasting).
• Older age at IBD diagnosis.

Ulcerative colitis patients have lower risk than Crohn’s, but risk is still elevated, possibly due to associated primary sclerosing cholangitis (PSC) which itself causes biliary sludge and stones.

Clinical presentation – differentiating from IBD flare

Gallstone symptoms in IBD can be mistaken for an IBD exacerbation. Key distinctions:

• Biliary colic: Postprandial (especially after fatty meals), right upper quadrant pain radiating to right shoulder or back, lasting 30 min to 6 hours. No fever or leukocytosis.
• Acute cholecystitis: Constant RUQ pain, fever, Murphy’s sign, elevated WBC. May occur without a clear fatty meal trigger.
• IBD flare: Diarrhoea (often bloody in UC), crampy diffuse abdominal pain, urgency, weight loss. RUQ pain is not typical unless there is associated PSC or gallstones.

If an IBD patient presents with RUQ pain, fever, or abnormal LFTs (especially elevated alkaline phosphatase), gallstones must be ruled out before attributing to IBD.

Diagnosis – imaging and pitfalls

Same as general population, but with special considerations:

• Ultrasound: First‑line. High sensitivity for gallstones (95%). May also detect biliary sludge, wall thickening, pericholecystic fluid.
• MRCP: Useful if common bile duct stones are suspected (elevated bilirubin, ALP). Non‑invasive and avoids radiation.
• EUS: High sensitivity for CBD stones, especially in non‑dilated ducts. Can also assess for PSC.
• ERCP: Therapeutic for CBD stones. Higher risk of post‑ERCP pancreatitis in IBD? Not proven, but caution needed if patient on immunomodulators.

Pitfall: IBD patients with PSC may have intrahepatic biliary strictures and sludge that mimic stones. MRCP is essential in these cases.

Management – cholecystectomy, perioperative considerations

Asymptomatic gallstones in IBD: Observation is safe, as in the general population. Prophylactic cholecystectomy is not recommended unless patient is undergoing abdominal surgery for other reasons (e.g., bowel resection).

Symptomatic gallstones: Laparoscopic cholecystectomy is the standard. However, IBD patients have special perioperative risks:

• Immunosuppressive medications: Steroids (prednisone) increase infection risk and impair wound healing. Ideally, taper to lowest effective dose before surgery. Biologics (anti‑TNF, vedolizumab, ustekinumab) – current guidelines recommend continuing them, but some surgeons prefer to hold one dose perioperatively (controversial).
• Nutritional status: Malnourished patients (hypoalbuminemia) have higher complication rates. Preoperative optimisation (enteral nutrition, parenteral nutrition if needed) is advised.
• Intra‑abdominal adhesions: Prior abdominal surgeries (common in Crohn’s) increase risk of conversion from laparoscopic to open cholecystectomy.
• Infectious complications: Higher risk of surgical site infection, intra‑abdominal abscess. Prophylactic antibiotics and careful sterile technique are essential.

If common bile duct stones are present: ERCP with sphincterotomy and stone extraction, followed by cholecystectomy (same admission or delayed).

Prevention – UDCA (ursodiol) for high‑risk patients

Ursodeoxycholic acid (UDCA) reduces cholesterol saturation and may prevent gallstone formation in high‑risk IBD patients. Evidence:

• Post‑ileal resection: Small trials suggest UDCA (10‑15 mg/kg/day) reduces biliary sludge and gallstone formation, but no large RCT. Some experts recommend UDCA for patients with ileal resection >50 cm or recurrent stones.
• TPN‑associated gallstones: UDCA is effective in preventing sludge and stones during TPN (evidence stronger).
• Primary sclerosing cholangitis (PSC): UDCA is used for PSC (though not FDA‑approved) and may reduce biliary sludge, but does not prevent cholangiocarcinoma.
• Routine prophylaxis in all IBD: Not recommended.

Other preventive measures: avoid prolonged fasting, maintain nutrition, consider cholecystectomy during other abdominal surgery if patient has gallstones (even asymptomatic) – but this is debated.

Interactive FAQ – IBD and gallstones

Disclaimer: This information is for educational purposes. Management of gallstones in IBD requires close collaboration between gastroenterologists and surgeons. Consult a specialist at Vivekananda Hospital for personalised care.